Thermo Fisher Scientific Inc. (TMO)
Boston Trust Walden Corp Buys 3,873 Shares of Thermo Fisher Scientific Inc. $TMO
Boston Trust Walden Corp lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 9.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,973 shares of the medical research company's stock after purchasing an additional
Thermo Fisher: Great Business Still Trading At A Risky Price Before Earnings
Thermo Fisher Scientific (TMO) remains a high-quality, stable business, but its stock is currently overvalued relative to its growth outlook. TMO reported FY25 revenue growth of 3.9% and EPS growth of 7.3%, with management guiding for 6–8% adjusted EPS growth in FY26. Despite solid fundamentals and resilient end-markets, valuation multiples near 30x earnings/free cash flow appear stretched unless double-digit growth resumes.
Unlocking Q1 Potential of Thermo Fisher (TMO): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Thermo Fisher heads into Q1 earnings with Life Sciences Solutions growth in focus, as bioproduction strength and new innovations may drive results.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher Stock May Benefit Following Collaboration With PRECISE
TMO teams up with PRECISE on a major proteomics study, expanding its role in large biobank projects and precision medicine initiatives.
TMO Stock May Benefit From New Gibco CTS Portfolio Addition
Thermo Fisher unveils the Gibco CTS Compleo system to automate cell therapy manufacturing, targeting efficiency gains and consistency as demand in the fast-growing market rises.
TMO Stock May Gain From the Rollout of Gibco CHOvantage GS CLD Kit
Thermo Fisher may gain as it unveils its Gibco CHOvantage GS CLD Kit to speed biologics development, cut costs and boost cell culture growth.
Thermo Fisher: A High-Quality Life Science Platform Positioned For Growth
Thermo Fisher shares have declined ~20% YTD, presenting an attractive long-term entry point given its resilient business model and broad platform. TMO's diversified segments, recurring consumables revenue, and strong M&A track record underpin its competitive advantage across the life sciences value chain. Despite cautious FY26 guidance (4–6% revenue growth), TMO's EBITDA margin has normalized, and long-term demand drivers remain robust.
Bamco Inc. NY Lowers Stake in Thermo Fisher Scientific Inc. $TMO
Bamco Inc. NY reduced its position in Thermo Fisher Scientific Inc. (NYSE: TMO) by 19.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,712 shares of the medical research company's stock after selling 6,054 shares during the period. Bamco Inc.
Cinctive Capital Management LP Makes New $3.37 Million Investment in Thermo Fisher Scientific Inc. $TMO
Cinctive Capital Management LP bought a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 6,938 shares of the medical research company's stock, valued at approximately $3,365,000. Other hedge
